New Risk • Jul 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 102% per year over the past 5 years. Market cap is less than US$10m (US$9.61m market cap). Reported Earnings • Jul 01
First half 2026 earnings released: EPS: S$0.014 (vs S$0.02 loss in 1H 2025) First half 2026 results: EPS: S$0.014 (up from S$0.02 loss in 1H 2025). Revenue: S$8.42m (up 67% from 1H 2025). Net income: S$269.3k (up S$586.4k from 1H 2025). Profit margin: 3.2% (up from net loss in 1H 2025). New Risk • Jun 30
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Over 11x increase in shares outstanding. This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 102% per year over the past 5 years. Shareholders have been substantially diluted in the past year (over 11x increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (14% average weekly change). New Risk • Jun 28
New major risk - Revenue and earnings growth Earnings have declined by 102% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 102% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Market cap is less than US$100m (US$10.8m market cap). New Risk • Jun 05
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: US$9.11m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$9.11m market cap). Minor Risk Share price has been volatile over the past 3 months (16% average weekly change). 공고 • Jun 05
Basel Medical Group Ltd Announces CFO Changes The Board of Directors of Basel Medical Group Ltd. has appointed Mr. Neo Chun How Alton as its new interim Chief Financial Officer effective June 2, 2026. Mr. Neo was appointed as interim CFO to replace Ms. Jianing Lu, the CFO of the Company. Ms. Lu resigned from her position as CFO of the Company. Mr. Neo is a finance professional with extensive experience in corporate leadership, financial management, and education. Prior to joining Basel Medical, Alton served as the deputy CEO of InCorp Global's Singapore operations, where he oversaw the entire Singapore's operations - in particular, advisory and outsourcing services. In this role, he provides expertise in management reporting, corporate restructuring, business valuation, insolvency, and forensic accounting. Before his tenure at InCorp Global, Mr. Neo contributed to the Singapore Ministry of Finance as a tax policy associate, focusing on the development and review of tax incentives. He was also part of the pioneer team at the Singapore Accountancy Commission (now ACRA) that developed the Singapore Chartered Accountant Qualification Programme. In addition to his corporate roles, Mr. Neo is dedicated to education, having developed and taught courses in financial accounting and related subjects at leading tertiary institutions. Currently, he serves as a part-time tutor at the London School of Business & Finance in Singapore and Singapore University of Social Sciences. Mr. Neo holds a Master of Business Administration, University of Hull and is also a Chartered Valuer, Institute of Valuers and Appraisers, CA Singapore, Institute of Singapore Chartered Accountants and CPA Australia. 
